Dr. Pedro Romero, Chief Medical & Scientific Officer at Novigenix said, “Our findings represent a paradigm shift in colorectal cancer diagnostics. By uncovering previously unknown immune alterations, we are advancing early detection capabilities and reaffirming Novigenix’s commitment to integrating immune system insights into personalized cancer care.”

CRC is the second leading cause of cancer-related mortality worldwide, claiming nearly one million lives annually. Prevention and early diagnosis are critical for reducing mortality, yet current circulating tumor DNA (cfDNA)-based liquid biopsies face limitations, particularly in detection of high risk precancerous colonic adenoma and early CRC stages, due to their dependence on tumor-derived signals. Novigenix’s Liquid ImmunoTranscriptomic Platform LITOSeek™ addresses these limitations by capturing the host immune response to onset of oncogenesis as a sensitive and alternative approach for early CRC detection.

Using cutting-edge whole transcriptome analysis of peripheral blood mononuclear cells (PBMCs), the study identified 226 novel RNA biomarkers revealing systemic immune modulation alongside the progression of CRC. These findings provide compelling evidence of systemic immune modulation even in pre-malignant adenomas, laying the foundation for development of next-generation blood tests for early CRC screening.

Professor Andres Perez Uribe, Professor of Data Science and Computational Science at the University of Applied Sciences in Switzerland (HEIG-VD/HES-SO) said, “This study demonstrates how interdisciplinary collaboration between computational science and oncology can lead to transformative breakthroughs. By leveraging advanced computational techniques to analyze large transcriptomic datasets, we have been able to uncover novel biomarkers that hold the promise of revolutionizing early colorectal cancer detection.”

For over a decade, Novigenix has championed the integration of immune system intelligence into cancer diagnostics, pioneering the use of liquid biopsy mRNA immune profiling. This innovative approach is setting a new standard in predictive modeling, enabling unparalleled insights into tumor-immune interactions for early detection of cancer and development of novel cancer therapeutics.